Lana Pine

April Armstrong, MD, MPH, explains the effectiveness of interleukin (IL)-17 and IL-23 inhibitors in treating moderate to severe plaque psoriasis and psoriatic arthritis.

Mona Shahriari, MD, and Andrew F Alexis, MD, MPH, discussed the multifaceted considerations dermatologists should weigh when treating patients with skin of color diagnosed with plaque psoriasis.

Susan C. Taylor, MD, emphasizes the importance of understanding the unique biological differences and needs of individuals with skin of color.

Results of several clinical trials demonstrated the superior efficacy of risankizumab compared with apremilast or placebo.

Benjamin Lockshin, MD, explains the current landscape of oral medications for plaque psoriasis, emerging developments in treatment, and the importance of shared decision-making.

Achievement of minimal disease activity and remission were observed in approximately half of patients with psoriatic arthritis receiving upadacitinib.

The approval of the intravenous formulation of secukinumab allows healthcare providers to better tailor treatment to their patients’ unique needs. 

Providers identified an increased administrative workload and inadequate biosimilar device training as pain points during a mandatory switch to a biosimilar.

The proposed denosumab biosimilar, SB16, demonstrated pharmacokinetic bioequivalence, as well as equivalent efficacy, safety, and immunogenicity,

Results of a recent systematic review demonstrated no difference in the immunogenicity rates and safety profiles in patients who switched to a biosimilar and those who continued to receive the reference product.

Feldman discusses the importance of self-education and open communication between patient and physician to help stay informed about relevant laws.

Feldman explains how healthcare legislation and regulation play a pivotal role in shaping patient care and costs.

Madelaine Feldman, MD, discusses the role pharmacy benefit managers play in delaying patient care.

While the results showed a high prevalence of suspected musculoskeletal symptoms in patients with psoriasis, only a small number were due to psoriatic arthritis.

Hematologic malignancy was not affected by the type of biologics prescribed, treatment patterns, comedications, comorbidities, or cumulative defined daily doses.

In patients initiating allopurinal, adverse events were more common in those receiving concomitant colchicine or nonsteroidal anti-inflammatory drugs compared to those without prophylaxis.

The Patient Self-Report Survey for the Assessment of Fibromyalgia illustrated its accuracy in determining pain sensitivity and psychological factors in patients with shoulder or low back pain.

Patients with psoriatic disease have a significantly higher risk of developing a variety of autoimmune diseases, as indicated by the Charlson Comorbidity Index.

Self-injection of bimekizumab was generally well tolerated among patients with psoriatic arthritis.

Retention rates for golimumab treatment at the 5-year mark were consistently high when used as a first-line therapy and did not significantly differ across conditions.

The overall cardiovascular burden was significantly higher in the fibromyalgia cohort when compared with the general Italian population.

At week 52, sustained remission was observed in significantly more patients receiving sarilumab compared with placebo.

Results demonstrated comparable safety, immunogenicity, and pharmacokinetics between adalimumab-afzb and the reference product.

The rheumatology month in review highlights top data from the 2023 CCR West, CBT for reducing pain catastrophizing in patients with fibromyalgia, and the link between gout and a reduced likelihood of Alzheimer Disease.

The biosimilar month in review highlights an interview with leading experts, the latest data regarding switching between biologics and biosimilars, and the efficacy of infliximab biosimilars among patients with inflammatory conditions.

A systematic literature search reported an increase in both publications and cases of spinal gout.

At week 16, no significant differences in response rates were observed regarding the adalimumab biologic and biosimilars.

Although the dietary intervention did not significantly reduce overall serum urate, it did decrease levels among those with baseline hyperuricemia.

Despite commonly understood symptoms and efficacious treatments, the stigmatizing nature of gout has caused significant setbacks to curbing its impact on Americans.

At the 6-month mark, a significant reduction was reported in both the widespread pain index and the symptom severity scale in patients with fibromyalgia undergoing a gluten-free diet.